Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

Immune checkpoint inhibitors (ICIs) have improved the treatment of several cancers. These
drugs increase T-cell activity and the antitumor immune response but also have immune …

Importance Better understanding of the emergency care needs of patients with cancer will
inform outpatient and emergency department (ED) management. Objective To provide a …

A robust understanding of the tumor immune environment has important implications for
cancer diagnosis, prognosis, research, and immunotherapy. Traditionally …

Checkpoint inhibitors are part of the family of immunotherapies and are increasingly being
used in a wide variety of cancers. Immune-related adverse events pose a major challenge in …

Introduction Immune-mediated toxicities are potentially fatal and can affect virtually any
organ system. The prevalence of immune-mediated toxicity in patients being treated with …

The immunotherapy revolution in cancer treatment involves a variety of specialists, not only
oncologists, but also internal medicine physicians, endocrinologists, dermatologists …

Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint
inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune …

PURPOSE Increasing use of immune checkpoint inhibitors (ICIs) in routine cancer care will
increase the incidence of immune-related adverse events (irAEs). Systems are needed to …

Rapid advances in cancer immunotherapy using immune checkpoint inhibitors have led to
significantly improved survival. Rapid identification of the toxicity syndromes associated with …